# Sepsis Prognosis and Diagnosis in the Emergency Department (SPEED)

> **NCT05639504** · — · WITHDRAWN · sponsor: **Inflammatix**

## Conditions studied

- Respiratory Tract Infections
- Urinary Tract Infections
- Intra-Abdominal Infections
- Skin and Soft Tissue Infection
- Suspected Meningitis/Encephalitis or Any Other Infection
- Sepsis

## Interventions

- **DIAGNOSTIC_TEST:** IMX-BVN-4 and IMX-SEV-4

## Key facts

- **NCT ID:** NCT05639504
- **Lead sponsor:** Inflammatix
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-12
- **Primary completion:** 2023-04
- **Final completion:** 2023-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study never started, change in company focus on US
- **Last updated:** 2023-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05639504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05639504, "Sepsis Prognosis and Diagnosis in the Emergency Department (SPEED)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05639504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*